Altech Batteries Ltd has showcased its CERENERGY® battery technology at Hannover Messe 2025, the world’s leading industrial trade fair. The company featured in the dedicated Energy Storage Hall, drawing significant interest from industry leaders, prospective partners, and investors.
Hannover Messe attracts more than 200,000 visitors and 6,500 exhibitors annually, providing a prominent global platform for industrial innovation. Altech used the opportunity to introduce its CERENERGY® solid-state sodium alumina battery technology to a diverse international audience within the energy storage sector.
Latrobe Magnesium Ltd is aiming to restart its demonstration plant in late May, with plans to commence production of magnesium oxide (MgO) and progress towards steady-state operations.
The company has secured A$2.75 million through an institutional placement and launched a fully underwritten Share Purchase Plan (SPP) to raise an additional A$750,000, bringing the total capital raising to A$3.5 million. Latrobe will issue 250 million new shares at $0.011 per share, representing a 15.4% discount to the last traded price of $0.013 per share.
Aldeyra Therapeutics (NASDAQ:ALDX) shares plummeted more than 70% after the biotechnology company received a letter of refusal from the Food and Drug Administration (FDA) for its investigational dry eye disease therapy reproxalap.
The company said the rejection was based on insufficient evidence of efficacy in treating ocular symptoms associated with dry eye disease.
Excellon Resources Inc (TSX:EXN, OTCQB:EXNRF) has reported progress in securing offtake-linked financing to support the restart of operations at the Mallay Silver Mine in Peru.
The company said it has received multiple non-binding proposals from leading trading houses for zinc and lead concentrate offtake agreements.
T Stamp Inc (NASDAQ:IDAI, EURONEXT:AIID) (dba Trust Stamp) said it has been selected to participate in the CyberBoost Catalyse program, an initiative supporting high-growth cybersecurity companies in expanding across Singapore, the Asia-Pacific (APAC) region, the UK, and other global markets.
The program, led by the CyberSG Talent, Innovation and Growth (TIG) Collaboration Centre and powered by UK-based innovation firm Plexal, is backed by the Cyber Security Agency of Singapore (CSA) and the National University of Singapore (NUS).
Nostra Terra Oil and Gas Company PLC (AIM:NTOG, OTC:NTOGF) is now preparing for the drilling of the Fouke-3 well, after approval among joint venture partners.
The AIM-quoted firm holds a 32.5% interest in the project, where operations are expected to begin in the third quarter of 2025.
Synairgen PLC (AIM:SNG, OTC:SYGGF), a biotech company developing an experimental inhaled treatment for respiratory infections, says its shares will remain freely tradeable - even after its recent move to go private.
The company, best known for its investigational drug SNG001, updated investors following a vote last week to delist from AIM and become a private limited company.
West Wits Mining Ltd has launched a comprehensive strategic review across the entirety of its Witwatersrand Basin Project (WBP) in South Africa in response to booming gold prices, which have recently topped US$3,000 per ounce.
At the same time, there are ongoing efforts to finalise funding for the company’s near-term production focus at the Qala Shallows gold project.
Resolution Minerals Ltd has increased its understanding of the Drake East Antimony-Gold Project in New South Wales, having wrapped up a high-resolution Light Detection and Ranging (LiDAR) survey and interpretation.
The Drake East Project is considered a high-potential brownfields asset with historical antimony production and numerous documented high-grade gold occurrences.
Patient enrolment at Southside Cancer Care Centre in Miranda, New South Wales has started marking the activation of Race Oncology Ltd’s lead Australian site for the Phase 1 clinical trial of RC220 in combination with doxorubicin for patients with advanced solid tumours.
The open-label, multi-centre study is designed to assess human safety and pharmacokinetic data, determine the maximum tolerated combined dose (MTCD) of RC220 and doxorubicin, and deliver early clinical insights into RC220’s cardioprotective, anticancer and N6-methyladenosine (m6A) RNA-modifying activity.